Interventional therapies for chronic heart failure: An overview of recent developments

Bingchen Guo1, Si Shi2, Yutong Guo1

  • 1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, China.

ESC Heart Failure
|November 11, 2024
PubMed

Insights

Interventional therapies offer new hope for heart failure (HF) patients, improving outcomes beyond traditional drug treatments. Advancements like valve repair and ventricular assist devices are transforming HF management.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Technology

Background:

  • Heart failure (HF) is a significant global health issue, leading to high patient morbidity and mortality.
  • Existing pharmacological treatments for HF often yield suboptimal clinical outcomes.
  • There is a critical need for advanced therapeutic strategies to improve the prognosis of HF patients.

Purpose of the Study:

  • To review recent advancements in interventional therapies for chronic heart failure (HF).
  • To provide an overview of novel treatment modalities transforming HF management.
  • To highlight the potential of interventional approaches in improving patient outcomes.

Main Methods:

  • Review of current literature on interventional therapies for chronic heart failure.
  • Analysis of emerging technologies including transcatheter valve interventions and mechanical circulatory support.
  • Synthesis of data on neuromodulation techniques for HF treatment.

Main Results:

  • Transcatheter aortic valve replacement shows promise for severe aortic stenosis in HF patients.
  • Transcatheter mitral valve repair offers a less invasive option for chronic mitral regurgitation.
  • Left ventricular assist device implantation provides a viable option for advanced HF.
  • Neuromodulation therapy presents a novel approach for multifaceted HF treatment.

Conclusions:

  • Interventional therapies represent a significant advancement in managing chronic heart failure (HF).
  • These innovative treatments offer improved prognoses and quality of life for HF patients.
  • Continued research and development in interventional cardiology are crucial for addressing the HF epidemic.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
523
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2